Skip to content
Parakho

Kwality Pharmaceuticals Ltd

NSE KPLBSE 539997kwalitypharma.comInvestor relations

Q1 FY27, unaudited

Revenue
₹162.35 Cr
Profit after tax
₹25.62 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations162.35+45.63%503.08
Other income0.62+65.74%2.86
Total income162.97+45.70%505.94
Employee benefit expense14.74+21.30%54.04
Finance costs2.66−3.60%10.97
Depreciation & amortisation4.99+4.83%19.81
Total expenses128.99+36.02%415.62
Profit before tax33.99+99.60%89.49
Tax expense8.36+63.75%22.15
Profit after tax25.62+114.96%67.35
Total comprehensive income25.71+113.01%67.48
Earnings per share
Earnings per share, basic₹24.69₹64.90
Earnings per share, diluted₹24.69₹64.90

Q1 FY27 — unaudited, from the company’s filing with BSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with BSE. Source

FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Kwality Pharmaceuticals reported oncology revenue of INR30-35 crores for the quarter and reiterated a full-year FY27 revenue target of over INR700 crores with EBITDA margins between 26% to 27%. Management discussed registration progress across the general facility, oncology, biological and hormone units, and addressed debtor days, capex plans, and a proposed change of statutory auditor to KPMG. The company also detailed longer-term revenue expectations from its hormone, biosimilar and Erythropoietin programs extending to FY29 and FY30.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 39 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 10 Oct 2026.